Global Autoinjectors Market, 2016 - 2026 - Product Image

Global Autoinjectors Market, 2016 - 2026

  • ID: 3751526
  • Report
  • Region: Global
  • 380 Pages
  • Roots Analysis
1 of 5
The Global Autoinjectors Market Will Grow at an Annualized Growth Rate of Over 8% in the Next Ten Years

FEATURED COMPANIES

  • 3P Limited
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Medeca Pharma
  • PDL BioPharma
  • Sumitomo Dainippon Pharma
  • MORE
The ‘Global Autoinjectors Market, 2016-2026' report provides a comprehensive analysis of the current state of autoinjectors market and the likely future evolution of these devices over the next decade. Starting with an overview of self-administration devices, the report elaborates on the origin / history of autoinjectors, their components and advantages offered by different categories of autoinjectors.

It also covers information on needlestick injuries and looks at the safety laws and legislations across major regional markets for prefilled syringes that are incorporated as primary drug containers in autoinjectors.

One of the key objectives of the study is to enumerate various autoinjectors available in the market, combination products currently available / being developed and the corresponding market potential across different therapeutic areas. Amongst other elements, the report elaborates on the following key areas:

- The current state of the market with respect to key players, routes of administration, primary drug containers, usability, indications and drugs being targeted.
- 2 X 2 matrices depicting the product competitiveness and supplier power across the growing landscape of disposable and reusable autoinjectors.
- Detailed case studies on the drugs that have been potential targets for autoinjectors.
- List of likely candidates for delivery via autoinjectors based upon their route of administration, targeted indication and dosage regime.
- Detailed company profiles of the key autoinjector manufacturers as well as emerging players that are trying to build a foothold in this industry.
- The future growth opportunities likely to drive the market in the short term and long term.

The study also focuses on analyzing the existing market size and potential future growth of these drug delivery devices across different therapeutic classes, routes of administration and extent of usability. The report provides sales forecast for the overall autoinjectors market for the period 2016 - 2026. It takes into account the price variation that is likely to occur as a result of mass adoption and increased competition.

For the purposes of the study, we interviewed important stakeholders to solicit their opinions on upcoming opportunities and challenges that must be considered for a more inclusive growth. 2015 is the base year; actual figures have been sourced and analyzed from publicly available information. Unless otherwise specified, all figures are presented in USD.

Research Methodology

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

- Annual reports
- Investor presentations
- SEC filings
- Industry databases
- News releases from company websites
- Government policy documents
- Industry analysts’ views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of autoinjectors market.

Chapter 3 provides a general overview of the various self-injection devices and autoinjectors. It covers the historical evolution of autoinjectors, their components, categories and associated manufacturing/packaging processes. In addition, it elaborates on the benefits of autoinjectors that have led to a growing adoption over the last several years. The chapter also highlights the issue of needlestick injuries and various preventive laws worldwide that have put the focus on introducing safety features in these devices.

Chapter 4 includes an introduction on the types of primary drug containers that are utilized in autoinjectors. Broadly, it covers an overview on the current trends coming up in the market of prefilled syringes and cartridges. It also lists the key manufacturers of these primary drug containers.

Chapter 5 provides a comprehensive analysis of the current market of autoinjectors. It lists over 80 autoinjector devices (including variants) that can be used to carry out self-administration for a variety of application areas. For these devices, we have identified the type and volume of the primary drug container used, usability, route of administration, needle size and other technical parameters. The chapter also includes list of combination products that have been approved or are under development with respect to indications being targeted. For both disposable and reusable autoinjectors, we have presented 2 X 2 matrices to compare the relevant product competitiveness and supplier power.

Chapter 6 presents a list of therapeutic drugs that are currently available in autoinjectors. It also provides case studies on the most common drugs / indications targeted. In addition, we have put together a list of potential molecules, based upon the route of administration, indication targeted and dosage regime, which are likely to form the target drugs for delivery via autoinjectors in the future.

Chapter 7 provides detailed profiles of key autoinjector manufacturers highlighting information on the company overview, financial performance, technology overview, product portfolio, collaborations and recent developments. Key players covered in this section include (in alphabetical order) Bespak, DALI Medical Devices, Elcam Medical, Meridian Medical Technologies, Owen Mumford, SHL Group, Union Medico and Ypsomed Delivery Systems.

Chapter 8 discusses profiles of new entrants in the autoinjectors industry. These profiles cover information on their company overview, technology overview, product portfolio and recent developments. Emerging players covered in this section include (in alphabetical order) Amedra Pharmaceuticals, Kaleo Pharma, Nuance Design, Oval Medical Technologies, Xeris Pharmaceuticals and Zion Clinical Pharmacy.

Chapter 9 provides a detailed description of the likely evolution of autoinjectors market. We have adopted a ‘top down’ approach, backed by robust data and credible inputs from primary research, to identify the likely size of the market, both in terms of value (USD billion) and volume (number of devices).

Chapter 10 highlights the key future growth opportunities likely to increase market share of manufacturers active in this area. These include life cycle management, growing pipeline of biologics and biosimilars, emerging target indications, launch of autoinjectors in other regions and introduction of specific advanced and user friendly features in these devices.

Chapter 11 is a collection of interview transcripts. For the purpose of our study, we contacted number of stakeholders in order to ascertain the key strategic initiatives and future roadmap of the industry. These include Douglas Marenzi (Managing Director, PHC) and Tsachi Shaked (Senior Marketing and BD Director, Injectable Drug Delivery Devices, Elcam Medical). Other participants requested anonymity.

Chapter 12 summarizes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 14 is an appendix, which provides a list of companies and organizations mentioned in this report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3P Limited
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Medeca Pharma
  • PDL BioPharma
  • Sumitomo Dainippon Pharma
  • MORE
1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. Executive Summary

3. Introduction
3.1. Chapter Overview
3.2. Drug Delivery Devices
3.3. Conventional Parenteral Delivery Using a Needle and Syringe
3.4. Self-Administration: An Emerging Trend
3.4.1. Rising Burden of Chronic Diseases
3.4.2. Need for Immediate Treatment in Emergency Situations
3.4.3. Expansion of Injectable Biologic Products
3.5. Types of Self- Injection Devices
3.5.1. Prefilled Syringes
3.5.2. Pen-Injectors
3.5.3. Needle-Free Injectors
3.5.4. Autoinjectors
3.5.5. Large Volume Wearable Injectors
3.6. Self-Injection Devices Market
3.7. Needlestick Injuries
3.7.1. Incidence And Cost Burden
3.7.2. Prevention
3.7.3. Government Legislation for the Prevention of Needlestick Injuries
3.7.4. Safety Options in Self-Injectors
3.8. Autoinjectors: An Important Class of Self-Injection Devices
3.8.1. Components of Autoinjectors
3.8.2. Classification of Autoinjectors
3.8.2.1. On the Basis of Mechanism
3.8.2.2. On the Basis of Usability
3.8.2.3. On the Basis of Dose Delivered
3.8.3. Manufacturing/Packaging
3.8.4. Benefits of Autoinjectors
3.9. Regulatory Considerations
3.10. Drug Device Combination Products

4. Primary Drug Containers in Autoinjectors
4.1. Chapter Overview
4.2. Primary Drug Container
4.2.1. Vials
4.2.2. Cartridges
4.2.2.1. Components of Cartridges
4.2.2.2. Glass: Historical Material of Choice
4.2.2.3. Types of Cartridges
4.2.2.3.1. Single Chamber Cartridge
4.2.2.3.2. Dual Chamber Cartridge
4.2.2.4. Applications of Cartridges
4.2.2.5. Drawbacks of Cartridges
4.2.2.6. Companies Developing Cartridges
4.2.3. Prefilled Syringes
4.2.3.1. Components of Prefilled Syringes
4.2.3.2. Classification of Prefilled Syringes
4.2.3.2.1. Based on Barrel Material
4.2.3.2.2. Based on Number of Chambers
4.2.3.2.3. Based on Type of Needle
4.2.3.3. Prefilled Syringes: Key Benefits
4.2.3.3.1. Benefits over Traditional Injectable Devices
4.2.3.3.2. Benefits for Healthcare Professionals and End Users
4.2.3.3.3. Benefits for Manufacturers
4.2.3.4. Advantages of Plastic Prefilled Syringes
4.2.3.5. Prefilled Syringe Systems Available in the Market
4.2.3.5.1. Glass Prefilled Syringes
4.2.3.5.2. Plastic Prefilled Syringes

5. Autoinjectors: Current Market Landscape
5.1. Chapter Overview
5.2. Autoinjectors: Overall Market Overview
5.2.1. Autoinjectors: Distribution by Players
5.2.2. Autoinjectors: Distribution by Type of Primary Drug Container
5.2.3. Autoinjectors: Distribution by Usability
5.2.4. Autoinjectors: Distribution by Type of Dosage
5.2.5. Autoinjectors: Distribution by Route of Administration
5.3. Approved Combination Products: Overall Market Overview
5.3.1. Approved Combination Products: Distribution by Players
5.3.2. Approved Combination Products: Distribution by Target Indication
5.3.3. Approved Combination Products: Distribution by Type of Primary Drug Container
5.3.4. Approved Combination Products: Distribution by Usability
5.3.5. Approved Combination Products: Distribution by Route of Administration
5.3.6. Approved Combination Products: Distribution by Target Drug
5.4. Pipeline Combination Products: Overall Market Overview
5.5. Product Competitiveness Analysis
5.5.1. Product Competitiveness Analysis for Disposable Autoinjectors
5.5.2. Product Competitiveness Analysis for Semi-Disposable/ Reusable Autoinjectors

6. Case Studies
6.1. Chapter Overview
6.2. Drugs Available / Being Evaluated With Autoinjectors
6.3. Case Study I: Adrenaline/Epinephrine
6.3.1. Overview
6.3.2. Mechanism of Action
6.3.3. Anaphylaxis: Overview and Epidemiology
6.3.4. History of Development
6.3.5. Adrenaline/ Epinephrine Autoinjectors
6.3.5.1. Marketed Adrenaline/ Epinephrine Autoinjectors
6.3.5.1.1. Adrenaclick®
6.3.5.1.2. Allerject / Auvi-Q® (Formerly called e-cue™)
6.3.5.1.3. Anapen®
6.3.5.1.4. Emerade®
6.3.5.1.5. EpiPen®
6.3.5.1.6. Jext®
6.3.5.2. Adrenaline/ Epinephrine Autoinjectors Under Development
6.3.5.2.1. Oval Autoinjector
6.3.5.2.2. Abiliject
6.3.6. Other Dosage Forms
6.3.7. Historical Sales

6.4. Case Study II: Interferon beta-1a/ Interferon beta-1b (Multiple Sclerosis)
6.4.1. Overview
6.4.1.1. Interferon beta-1a
6.4.1.2. Interferon beta-1b
6.4.2. Mechanism of Action
6.4.3. Multiple Sclerosis: Overview and Epidemiology
6.4.4. History of Development
6.4.5. Interferon-beta Autoinjectors
6.4.5.1. Interferon beta-1a Autoinjectors
6.4.5.1.1. Avonex Pen®
6.4.5.1.2. PLEGRIDY Pen
6.4.5.1.3. Rebif ® Rebidose ®
6.4.5.1.4. RebiSmart™
6.4.5.1.5. Rebiject II®
6.4.5.2. Interferon beta-1b Autoinjectors
6.4.5.2.1. BETACONNECT™
6.4.5.2.2. BETAJECT® Comfort/ Betacomfort®
6.4.5.2.3. Betaject® Lite
6.4.5.2.4. ExtaviJect® 30G/ ExtaviPro® 30G
6.4.6. Other Dosage Forms
6.4.7. Historical Sales
6.4.7.1. Interferon beta-1a
6.4.7.2. Interferon beta-1b

6.5. Likely Targets for Autoinjectors
6.5.1. Marketed Molecules
6.5.1.1. Marketed Molecules: Most Likely Candidates for Autoinjectors
6.5.1.2. Marketed Molecules: Likely Candidates for Autoinjectors
6.5.1.3. Marketed Molecules: Less Likely Candidates for Autoinjectors
6.5.2. Pipeline Molecules
6.5.2.1. Pipeline Molecules: Most Likely Candidates for Autoinjectors
6.5.2.2. Pipeline Molecules: Likely Candidates for Autoinjectors
6.5.2.3. Pipeline Molecules: Less Likely Candidates for Autoinjectors

7. Key Players
7.1. Chapter Overview
7.2. Bespak
7.2.1. Company Overview
7.2.2. Financial Performance
7.2.3. Technology Overview
7.2.4. Product Portfolio
7.2.4.1. Autoinjectors
7.2.4.1.1. Syrina™
7.2.4.1.2. ASI™ Autoinjector
7.2.4.1.3. OTS™ Autoinjector
7.2.5. Recent Developments
7.2.5.1. Collaborations
7.2.5.1.1. Aesica Pharmaceuticals
7.2.5.1.2. Undisclosed Global Generic Company
7.2.5.1.3. Undisclosed Global Pharmaceutical Company
7.2.5.1.4. Martindale Products and Specials
7.2.6. Future Outlook

7.3. Changzhou Delfu Technology
7.3.1. Company Overview
7.3.2. Financial Performance
7.3.3. Product Portfolio
7.3.3.1. Autoinjectors: Overview and Specifications
7.3.3.1.1. Components of Delfu Autoinjectors
7.3.3.1.2. Applications of Delfu Autoinjectors
7.3.3.1.3. Features of Delfu Autoinjectors
7.3.3.1.4. Advantages of Delfu Autoinjectors
7.3.3.1.5. Specifications of Delfu Autoinjectors
7.3.3.2. Autoinjectors: Product Details
7.3.3.2.1. YZ-II 3mLCartridge Digital Dose Setting GF Autoinjector
7.3.3.2.2. DZ-IA 3 mL Cartridge Needle Hidden Vaccination Autoinjector
7.3.3.2.3. DZ-IA Auto Injector Pen
7.3.3.2.4. YZ-III Standard 3 mL Cartridge Reusable Electronic Auto Injector Pen
7.3.3.2.5.YZ-III 0.001mL Dose Increments Fully Automated Reusable Injectors
7.3.3.2.6.YZ-III 0.001 mL Dose Accuracy Auto Injector Pen
7.3.3.2.7.YZ-II 3mL* 1u Auto inject Pen
7.3.3.2.8.YZ-V 3 mL Cartridge Replaceable Variable-dose Classic Auto Injector Pen
7.3.3.2.9.YZ-III Automatic Reusable Insulin Injection Pen

7.4. DALI Medical Devices
7.4.1. Company Overview
7.4.2. Product Portfolio
7.4.2.1. Autoinjectors
7.4.2.1.1. SAN-L
7.4.2.1.2. SAN-P
7.4.2.1.3. SAN-DV
7.4.2.1.4. SAN-DV Pro

7.5. Elcam Medical (E3D Elcam Drug Delivery Devices)
7.5.1. Company Overview
7.5.2. Product Portfolio
7.5.3. Autoinjectors
7.5.3.1. Flexi-Q Disposable Autoinjectors
7.5.3.1.1. Flexi-Q PFS
7.5.3.1.2. Flexi-Q HV
7.5.3.1.3. Flexi -Q DV
7.5.3.2. Flexi-Q Reusable Autoinjectors
7.5.3.2.1. Flexi-Q mMU
7.5.3.2.2. Flexi-Q eMU
7.5.3.3. Comparison of Elcam Medical Autoinjectors
7.5.4. Recent Developments
7.5.4.1. Collaborations
7.5.5. Future Outlook

7.6. Meridian Medical Technologies
7.6.1. Company Overview
7.6.2. Product Portfolio
7.6.2.1. Antidote Treatment Nerve Agent, Autoinjector (ATNAA): Atropine and Pralidoxime Chloride Injection
7.6.2.2. AtroPen® Autoinjector: Atropine Injection
7.6.2.3. Diazepam Autoinjector C-IV: Diazepam Injection
7.6.2.4. DuoDote® Autoinjector: Atropine and Pralidoxime Chloride Injection
7.6.2.5. Morphine Autoinjector C-II: Morphine Sulfate Injection
7.6.2.6. Pralidoxime Chloride Autoinjector: Pralidoxime Chloride Injection
7.6.2.7. Comparison of Meridian Medical Technologies Autoinjectors
7.6.2.8. EpiPen®
7.6.2.9. ALSUMA® / Sumatriptan Autoinjector
7.6.2.10. Vanquix™ Autoinjector
7.6.2.11. Investigational Midazolam Autoinjector
7.6.3. Technology
7.6.4. Future Outlook

7.7. Owen Mumford
7.7.1. Company Overview
7.7.2. Product Portfolio
7.7.2.1. Autoinjectors
7.7.2.1.1. Autoject® Micro
7.7.2.1.2. Autoject® 2
7.7.2.1.3. Autoject® Mini
7.7.2.1.4. Autoject Uni
7.7.2.1.5. Autoject Multi
7.7.2.1.6. Autoject® Flex
7.7.3. Future Outlook

7.8. Scandinavian Health Limited (SHL) Group
7.8.1. Company Overview
7.8.2. Product Portfolio
7.8.2.1. Two-Step Disposable Autoinjectors
7.8.2.1.1. Amber® (Pushclick™ Technology)
7.8.2.1.2. Molly®
7.8.2.1.3. Molly®RNS
7.8.2.1.4. Molly® 2.25
7.8.2.1.5. Molly® C
7.8.2.1.6. NAISA® (Negasai™ Spring Technology)
7.8.2.1.7. Comparison of SHL Two-Step Autoinjectors
7.8.2.2. Three-Step Disposable Autoinjectors
7.8.2.2.1. DAI®
7.8.2.2.2. DAI®-RNS
7.8.2.2.3. DAI®-R
7.8.2.2.4. SDI-MIX®+NIT™ (Needle Isolation Technology and Twist and Mix Mechanism)
7.8.2.2.5. VSDI-MIX™
7.8.2.2.6. PSDI®
7.8.2.2.7. Comparison of SHL Three-Step Autoinjectors
7.8.2.3. PPI® Injector (Rotaject™ Pressure Release Technology)
7.8.3. Recent Developments
7.8.4. Collaborations
7.8.5. Future Outlook

7.9. Union Medico
7.9.1. Company Overview
7.9.2. Technology
7.9.3. Product Portfolio
7.9.3.1. 45° Autoinjector
7.9.3.1.1. 45°/S Autoinjector
7.9.3.1.2. 45°/M Autoinjector
7.9.3.1.3. 45°/R Autoinjector
7.9.3.1.4. Comparison of 45° Autoinjectors
7.9.3.2. 90° Autoinjector
7.9.3.2.1. 90°/S Autoinjector
7.9.3.2.2. 90°/ M Autoinjector
7.9.3.2.3. 90°/ XL Autoinjector
7.9.3.2.4. SuperGrip™ Autoinjector
7.9.3.2.5. Exclusive™ Autoinjector
7.9.3.2.6. Comparison of 90° Autoinjectors
7.9.4. Future Outlook

7.10. Ypsomed
7.10.1. Company Overview
7.10.2. Financial Performance
7.10.3. Product Portfolio
7.10.3.1. Pen-Injectors
7.10.3.2. Autoinjectors
7.10.3.2.1.YpsoMate® and YpsoMate® 2.25
7.10.3.2.2.VarioJect™
7.10.3.2.3.YpsoMate® Smart
7.10.3.3. Comparison of Ypsomed Autoinjectors
7.10.4. Recent Developments
7.10.4.1. Investment in Solothurn Facility
7.10.4.2. Development of a New Generation of Injection and Infusion Systems
7.10.4.3. Formative Study of Ypsomed Disposable Autoinjector: Results
7.10.4.4. Plan to Increase Production Capacity
7.10.4.5. Geographical Expansion
7.10.5. Collaborations
7.10.5.1. Thinfilm Electronics
7.10.5.2. Tonghua Dongbao Pharmaceutical
7.10.5.3. Terumo Corporation
7.10.5.4. Hanmi Pharmaceutical
7.10.6. Future Outlook

8. Emerging Players
8.1. Chapter Overview
8.2. Amedra Pharmaceuticals (Impax Laboratories)
8.2.1. Company Overview
8.2.2. Product Portfolio
8.2.2.1. Adernaclick® Autoinjector

8.3. Kaleo Pharma
8.3.1. Company Overview
8.3.2. Product Portfolio
8.3.2.1. Auvi-Q® /Allerject
8.3.2.2. EVZIO® Autoinjector
8.3.3. Recent Developments

8.4. Nuance Designs
8.4.1. Company Overview
8.4.2. Technology Overview
8.4.3. Product Portfolio
8.4.3.1. Fusion™ Autoinjector
8.4.3.2. Quantum™ Autoinjector

8.5. Oval Medical Technologies
8.5.1. Company Overview
8.5.2. Technology Overview
8.5.3. Product Portfolio
8.5.4. Recent Developments

8.6. Xeris Pharmaceuticals
8.6.1. Company Overview
8.6.2. Technology Overview
8.6.3. Product Portfolio
8.6.3.1. G-Pen™ Autoinjector
8.6.3.2. DiazePen™ Autoinjector
8.6.4. Recent Developments

8.7. Zion Clinical Pharmacy
8.7.1. Company Overview
8.7.2. Product Portfolio

9. Global Autoinjectors Market Forecast, 2016 - 2026
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Overall Autoinjectors: Market Size and Forecast
9.3.1. Regional Market Size and Forecast: US, Europe, Asia Pacific and Rest of the World
9.3.2. Overall Disposable Autoinjectors: Market Size and Forecast
9.3.3. Overall Reusable Autoinjectors: Market Size and Forecast
9.3.4. Overall Subcutaneous Autoinjectors: Market Size and Forecast
9.3.5. Overall Intramuscular Autoinjectors: Market Size and Forecast
9.4. Autoinjectors for Anaphylaxis: Market Size and Forecast
9.4.1. Disposable Autoinjectors for Anaphylaxis: Market Size and Forecast
9.4.2. Reusable Autoinjectors for Anaphylaxis: Market Size and Forecast
9.4.3. Subcutaneous Autoinjectors for Anaphylaxis: Market Size and Forecast
9.4.4. Intramuscular Autoinjectors for Anaphylaxis: Market Size and Forecast
9.5. Autoinjectors for Multiple Sclerosis: Market Size and Forecast
9.5.1. Disposable Autoinjectors for Multiple Sclerosis: Market Size and Forecast
9.5.2. Reusable Autoinjectors for Multiple Sclerosis: Market Size and Forecast
9.5.3. Subcutaneous Autoinjectors for Multiple Sclerosis: Market Size and Forecast
9.5.4. Intramuscular Autoinjectors for Multiple Sclerosis: Market Size and Forecast
9.6. Autoinjectors for Rheumatoid Arthritis: Market Size and Forecast
9.6.1. Disposable Autoinjectors for Rheumatoid Arthritis: Market Size and Forecast
9.6.2. Reusable Autoinjectors for Rheumatoid Arthritis: Market Size and Forecast
9.6.3. Subcutaneous Autoinjectors for Rheumatoid Arthritis: Market Size and Forecast
9.6.4. Intramuscular Autoinjectors for Rheumatoid Arthritis: Market Size and Forecast
9.7. Autoinjectors for Migraine: Market Size and Forecast
9.7.1. Disposable Autoinjectors for Migraine: Market Size and Forecast
9.7.2. Reusable Autoinjectors for Migraine: Market Size and Forecast
9.7.3. Subcutaneous Autoinjectors for Migraine: Market Size and Forecast
9.7.4. Intramuscular Autoinjectors for Migraine: Market Size and Forecast
9.8. Autoinjectors for Diabetes: Market Size and Forecast
9.8.1. Disposable Autoinjectors for Diabetes: Market Size and Forecast
9.8.2. Reusable Autoinjectors for Diabetes: Market Size and Forecast
9.8.3. Subcutaneous Autoinjectors for Diabetes: Market Size and Forecast
9.8.4. Intramuscular Autoinjectors for Diabetes: Market Size and Forecast
9.9. Autoinjectors for Other Diseases: Market Size and Forecast
9.9.1. Disposable Autoinjectors for Other Diseases: Market Size and Forecast
9.9.2. Reusable Autoinjectors for Other Diseases: Market Size and Forecast
9.9.3. Subcutaneous Autoinjectors for Other Diseases: Market Size and Forecast
9.9.4. Intramuscular Autoinjectors for Other Diseases: Market Size and Forecast

10. Future Growth Opportunities
10.1. Chapter Overview
10.2. Life Cycle Management
10.3. Growing Pipeline of Biologics and Biosimilars
10.4. Emerging Target Indications for Autoinjectors
10.5. Expansion/ Adoption in the Emerging Regions
10.6. Specific Pockets of Growth

11. Interview Transcripts
11.1. Chapter Overview
11.2. Douglas Marenzi, Managing Director, PHC Injection Device Technologies
11.3. Tsachi Shaked, Senior Marketing and BD Director, Injectable Drug Delivery Devices, Elcam Medical

12. Conclusion
12.1. A Rapidly Growing Market Improving Patient Satisfaction
12.2. Growing Pipeline of Biologics and Life Cycle Management are Amongst the Key Drivers of the Industry
12.3. Several Combination Products Have Been Approved and Many are under Development
12.4. Anaphylaxis Has Dominated the Market So Far; Multiple Sclerosis, Rheumatoid Arthritis, Migraine, Psoriasis and Diabetes Have Witnessed Rising Adoption
12.5. Continued Growth in Disposable Devices; Increase in Demand for Reusable Devices
12.6. Established Firms Leading the Market; New Entrants are Fostering Continued Innovation
12.7. Next Generation Autoinjectors are on Their Way
12.8. Despite Being Over Two Decades Old, Market is still Evolving with Significant Growth Expected in the Coming Decade
12.9. Concluding Remarks

13. Appendix 1: Tabulated Data

14. Appendix 2: List of Companies and Organizations

List of Figures

Figure 2.1 Market Evolution: 2016, 2021, 2026 (USD Million)

Figure 3.1 Types of Drug Delivery Systems

Figure 3.2 Types of Self-Injection Devices

Figure 3.3 Cartridge Based Autoinjectors v/s Prefilled Syringe Based Autoinjectors

Figure 3.4 Autoinjector: Components

Figure 3.5 Autoinjector: Classification

Figure 4.1 Dual Chamber Cartridge

Figure 4.2 Glass Prefilled Syringes: Advantages and Disadvantages

Figure 4.3 Plastic Prefilled Syringes: Advantages and Disadvantages

Figure 5.1 Autoinjectors: Distribution by Players

Figure 5.2 Autoinjectors: Distribution by Type of Primary Drug Container

Figure 5.3 Autoinjectors: Distribution by Usability

Figure 5.4 Autoinjectors: Distribution by Type of Dosage

Figure 5.5 Autoinjectors: Distribution by Route of Administration

Figure 5.6 Approved Combination Products: Distribution by Players

Figure 5.7 Approved Combination Products: Distribution by Indication

Figure 5.8 Approved Combination Products: Distribution by Type of Primary Drug Container

Figure 5.9 Approved Combination Products: Distribution by Usability

Figure 5.10 Approved Combination Products: Distribution by Route of Administration

Figure 5.11 Approved Combination Products: Distribution by Target Drug

Figure 5.12 Autoinjectors (Disposable): Product Competitiveness Analysis

Figure 5.13 Autoinjectors (Reusable): Product Competitiveness Analysis

Figure 6.1 Adrenaline / Epinephrine: History of Development

Figure 6.2 Adrenaline / Epinephrine: Historical Sales (USD Million), 2012 - 2014

Figure 6.3 Interferon beta-1a/Interferon beta-1b: History of Development

Figure 6.4 Interferon beta-1a: Historical Sales (USD Million), 2012 - 2014

Figure 6.5 Interferon beta-1b: Historical Sales (USD Million), 2012 - 2014

Figure 7.1 Bespak Sales (GBP Million), FY 2010-H1 2016

Figure 7.2 Bespak Injectables: Autoinjectors

Figure 7.3 Bespak Injectables: Syrina™ Autoinjectors

Figure 7.4 Delfu Autoinjectors: Components

Figure 7.5 Applications of Delfu Autoinjectors

Figure 7.6 DALI Medical Devices: Autoinjectors

Figure 7.7 SAN-L: Step Operations

Figure 7.8 SAN-P: Step Operations

Figure 7.9 SAN-DV: Step Operations

Figure 7.10 SAN-DV Pro: Step Operations

Figure 7.11 Elcam Medical: Products

Figure 7.12 Elcam Medical: Flexi-Q Autoinjectors

Figure 7.13 Flexi-Q PFS: Components

Figure 7.14 Flexi-Q PFS: Step Operations

Figure 7.15 Flexi-Q DV: Components

Figure 7.16 Flexi-Q DV: Step Operations

Figure 7.17 Flexi-Q mMU: Components

Figure 7.18 Flexi-Q eMU: Components

Figure 7.19 Flexi-Q mMU / Flexi-Q eMU: Step Operations

Figure 7.20 Meridian Medical Technologies: Autoinjectors

Figure 7.21 ATNAA: Step Operations

Figure 7.22 Diazepam Autoinjector C-IV: Step Operations

Figure 7.23 DuoDote® Autoinjector: Step Operations

Figure 7.24 Morphine Autoinjector: Step Operations

Figure 7.25 Pralidoxime Chloride Autoinjector: Step Operations

Figure 7.26 EpiPen®: Step Operations

Figure 7.27 ALSUMA® Autoinjector: Step Operations

Figure 7.28 Vanquix™ Autoinjector: Step Operations

Figure 7.29 Owen Mumford: Cartridge-Based Injection Pens

Figure 7.30 Owen Mumford: Autoinjectors

Figure 7.31 Autoject® Micro: Step Operations

Figure 7.32 Autoject® 2 Autoinjector: Step Operations

Figure 7.33 Autoject® Mini: Step Operations

Figure 7.34 Autoject® Uni: Step Operations

Figure 7.35 Autoject® Multi: Step Operations

Figure 7.36 Autoject® Flex: Step Operations

Figure 7.37 SHL Medical: Product Portfolio

Figure 7.38 SHL Medical: Prefilled Syringe Based Autoinjectors

Figure 7.39 SHL Medical: Cartridge Based Autoinjectors

Figure 7.40 SHL Medical: Two-Step Autoinjectors

Figure 7.41 SHL Medical Two-Step Autoinjectors: Step Operations

Figure 7.42 SHL Medical: Three-Step Autoinjectors

Figure 7.43 DAI®: Step Operations

Figure 7.44 DAI®-R: Step Operations

Figure 7.45 SDI-MIX®+NIT™: Step Operations

Figure 7.46 Union Medico: 45° Autoinjector Portfolio

Figure 7.47 Union Medico: Parts of 45°/R Autoinjector

Figure 7.48 Union Medico: Types of 45°/R Autoinjector

Figure 7.49 Union Medico: Types of 90° Autoinjectors

Figure 7.50 SuperGrip™ Autoinjector: Components

Figure 7.51 Exclusive™: Components

Figure 7.52 Ypsomed Sales (CHF Million), FY 2011- H1 2016

Figure 7.53 Ypsomed: Sales by Business Divisions, FY 2015 (CHF Million, %)

Figure 7.54 Ypsomed: Sales by Business Divisions, H1 2016 (CHF Million, %)

Figure 7.55 Ypsomed: Cartridge Based Pen-injectors

Figure 7.56 Ypsomed: Cartridge Based Dual Chamber Pen-injectors

Figure 7.57 Ypsomed: Prefilled Syringe or Cartridge Based Autoinjectors

Figure 7.58 YpsoMate®: Step Operations

Figure 7.59 VarioJect™: Step Operations

Figure 7.60 YpsoMate® Smart: Step Operations

Figure 8.1 XeriSol™ Technology: Working Mechanism

Figure 8.2 Trimix Autoinjector: Components

Figure 9.1 Overall Autoinjectors Market (Number of Units, Millions), 2016 - 2026

Figure 9.2 Overall Autoinjectors Market (USD Million), 2016 - 2026

Figure 9.3 Regional Autoinjectors Market (Number of Units, Millions), 2016 - 2026

Figure 9.4 Regional Autoinjectors Market (USD Million), 2016 - 2026

Figure 9.5 Overall Disposable Autoinjectors Market (Number of Units, Million), 2016 - 2026

Figure 9.6 Overall Disposable Autoinjectors Market (USD Million), 2016 - 2026

Figure 9.7 Overall Reusable Autoinjectors Market (Number of Units, Million), 2016 - 2026

Figure 9.8 Overall Reusable Autoinjectors Market (USD Million), 2016 - 2026

Figure 9.9 Overall Subcutaneous Autoinjectors Market (Number of Units, Million), 2016 - 2026

Figure 9.10 Overall Subcutaneous Autoinjectors Market (USD Million), 2016 - 2026

Figure 9.11 Overall Intramuscular Autoinjectors Market (Number of Units, Million), 2016 - 2026

Figure 9.12 Overall Intramuscular Autoinjectors Market (USD Million), 2016 - 2026

Figure 9.13 Autoinjectors for Anaphylaxis Market (Number of Units, Millions), 2016 - 2026

Figure 9.14 Autoinjectors for Anaphylaxis Market (USD Million), 2016 - 2026

Figure 9.15 Disposable Autoinjectors for Anaphylaxis (Number of Units, Million), 2016 - 2026

Figure 9.16 Disposable Autoinjectors for Anaphylaxis (USD Million), 2016 - 2026

Figure 9.17 Reusable Autoinjectors for Anaphylaxis (Number of Units, Million), 2016 - 2026

Figure 9.18 Reusable Autoinjectors for Anaphylaxis (USD Million), 2016 - 2026

Figure 9.19 Subcutaneous Autoinjectors for Anaphylaxis (Number of Units, Million), 2016 - 2026

Figure 9.20 Subcutaneous Autoinjectors for Anaphylaxis (USD Million), 2016 - 2026

Figure 9.21 Intramuscular Autoinjectors for Anaphylaxis (Number of Units, Million), 2016 - 2026

Figure 9.22 Intramuscular Autoinjectors for Anaphylaxis (USD Million), 2016 - 2026

Figure 9.23 Autoinjectors for Multiple Sclerosis Market (Number of Units, Million), 2016 - 2026

Figure 9.24 Autoinjectors for Multiple Sclerosis Market (USD Million), 2016 - 2026

Figure 9.25 Disposable Autoinjectors for Multiple Sclerosis (Number of Units, Million), 2016 - 2026

Figure 9.26 Disposable Autoinjectors for Multiple Sclerosis (USD Million), 2016 - 2026

Figure 9.27 Reusable Autoinjectors for Multiple Sclerosis (Number of Units, Million), 2016 - 2026

Figure 9.28 Reusable Autoinjectors for Multiple Sclerosis (USD Million), 2016 - 2026

Figure 9.29 Subcutaneous Autoinjectors for Multiple Sclerosis (Number of Units, Million), 2016 - 2026

Figure 9.30 Subcutaneous Autoinjectors for Multiple Sclerosis (USD Million), 2016 - 2026

Figure 9.31 Intramuscular Autoinjectors for Multiple Sclerosis (Number of Units, Million), 2016 - 2026

Figure 9.32 Intramuscular Autoinjectors for Multiple Sclerosis (USD Million), 2016 - 2026

Figure 9.33 Autoinjectors for Rheumatoid Arthritis Market (Number of Units, Million), 2016 - 2026

Figure 9.34 Autoinjectors for Rheumatoid Arthritis Market (USD Million), 2016 - 2026

Figure 9.35 Disposable Autoinjectors for Rheumatoid Arthritis (Number of Units, Million), 2016 - 2026

Figure 9.36 Disposable Autoinjectors for Rheumatoid Arthritis (USD Million), 2016 - 2026

Figure 9.37 Reusable Autoinjectors for Rheumatoid Arthritis (Number of Units, Million), 2016 - 2026

Figure 9.38 Reusable Autoinjectors for Rheumatoid Arthritis (USD Million), 2016 - 2026

Figure 9.39 Subcutaneous Autoinjectors for Rheumatoid Arthritis (Number of Units, Million), 2016 - 2026

Figure 9.40 Subcutaneous Autoinjectors for Rheumatoid Arthritis (USD Million), 2016 - 2026

Figure 9.41 Intramuscular Autoinjectors for Rheumatoid Arthritis (Number of Units, Million), 2016 - 2026

Figure 9.42 Intramuscular Autoinjectors for Rheumatoid Arthritis (USD Million), 2016 - 2026

Figure 9.43 Autoinjectors for Migraine Market (Number of Units, Million), 2016 - 2026

Figure 9.44 Autoinjectors for Migraine Market (USD Million), 2016 - 2026

Figure 9.45 Disposable Autoinjectors for Migraine (Number of Units, Million), 2016 - 2026

Figure 9.46 Disposable Autoinjectors for Migraine (USD Million), 2016 - 2026

Figure 9.47 Reusable Autoinjectors for Migraine (Number of Units, Million), 2016 - 2026

Figure 9.48 Reusable Autoinjectors for Migraine (USD Million), 2016 - 2026

Figure 9.49 Subcutaneous Autoinjectors for Migraine (Number of Units, Million), 2016 - 2026

Figure 9.50 Subcutaneous Autoinjectors for Migraine (USD Million), 2016 - 2026

Figure 9.51 Intramuscular Autoinjectors for Migraine (Number of Units, Million), 2016 - 2026

Figure 9.52 Intramuscular Autoinjectors for Migraine (USD Million), 2016 - 2026

Figure 9.53 Autoinjectors for Diabetes Market (Number of Units, Million), 2016 - 2026

Figure 9.54 Autoinjectors for Diabetes Market (USD Million), 2016 - 2026

Figure 9.55 Disposable Autoinjectors for Diabetes (Number of Units, Million), 2016 - 2026

Figure 9.56 Disposable Autoinjectors for Diabetes (USD Million), 2016 - 2026

Figure 9.57 Reusable Autoinjectors for Diabetes (Number of Units, Million), 2016 - 2026

Figure 9.58 Reusable Autoinjectors for Diabetes (USD Million), 2016 - 2026

Figure 9.59 Subcutaneous Autoinjectors for Diabetes (Number of Units, Million), 2016 - 2026

Figure 9.60 Subcutaneous Autoinjectors for Diabetes (USD Million), 2016 - 2026

Figure 9.61 Intramuscular Autoinjectors for Diabetes (Number of Units, Million), 2016 - 2026

Figure 9.62 Intramuscular Autoinjectors for Diabetes (USD Million), 2016 - 2026

Figure 9.63 Autoinjectors for Other Diseases Market (Number of Units, Million), 2016 - 2026

Figure 9.64 Autoinjectors for Other Diseases Market (USD Million), 2016 - 2026

Figure 9.65 Disposable Autoinjectors for Other Diseases (Number of Units, Million), 2016 - 2026

Figure 9.66 Disposable Autoinjectors for Other Diseases (USD Million), 2016 - 2026

Figure 9.67 Reusable Autoinjectors for Other Diseases (Number of Units, Million), 2016 - 2026

Figure 9.68 Reusable Autoinjectors for Other Diseases (USD Million), 2016 - 2026

Figure 9.69 Subcutaneous Autoinjectors for Other Diseases (Number of Units, Million), 2016 - 2026

Figure 9.70 Subcutaneous Autoinjectors for Other Diseases (USD Million), 2016 - 2026

Figure 9.71 Intramuscular Autoinjectors for Other Diseases (Number of Units, Million), 2016 - 2026

Figure 9.72 Intramuscular Autoinjectors for Other Diseases (USD Million), 2016 - 2026

Figure 10.1 Autoinjectors: Future Growth Opportunities

Figure 10.2 Numbers of Biologics Approved by the FDA, 2009-2015

Figure 12.1 Autoinjectors Market (2016, 2026): Distribution by Therapeutic Area (USD Million, #Millions)

Figure 12.2 Autoinjectors Market (2016, 2026): Distribution by Usability (USD Million, #Millions)

Figure 12.3 Autoinjectors Market (2016, 2026): Distribution by Route of Administration (USD Million, #Millions)

List of Tables

Table 3.1 Benefits of Autoinjectors

Table 4.1 Advantages of Glass as Barrel

Table 4.2 Companies Developing Cartridges

Table 4.3 Classification of Prefilled Syringes

Table 4.4 Glass Prefilled Syringes Available in the Market, 2015

Table 4.5 Plastic Prefilled Syringes Available in the Market, 2015

Table 5.1 List of Autoinjector Devices

Table 5.2 Autoinjectors: Distribution by Type of Dosage

Table 5.3 List of Approved Combination Products

Table 5.4 List of Pipeline Combination Products

Table 6.1 Drugs Available / Being Evaluated With Autoinjectors

Table 6.2 Adrenaline / Epinephrine: Commercially Available Autoinjectors

Table 6.3 Adrenaline /Epinephrine: Other Formulations

Table 6.4 Interferon beta-1a: Autoinjectors

Table 6.5 Interferon beta-1b: Autoinjectors

Table 6.6 Interferon-beta Drugs: Other Dosage Forms

Table 6.7 Marketed Molecules: Most Likely Candidates for Autoinjectors

Table 6.8 Marketed Molecules: Likely Candidates for Autoinjectors

Table 6.9 Marketed Molecules: Less Likely Candidates for Autoinjectors

Table 6.10 Pipeline Molecules: Most Likely Candidates for Autoinjectors

Table 6.11 Pipeline Molecules: Likely Candidates for Autoinjectors

Table 6.12 Pipeline Molecules: Less Likely Candidates for Autoinjectors

Table 7.1 Changzhou Delfu: Autoinjectors

Table 7.2 Delfu Autoinjectors: Specifications

Table 7.3 Elcam Medical: Comparison of Autoinjectors

Table 7.4 ATNAA: Constituents of Atropine Diluent (0.7mL)

Table 7.5 ATNAA: Constituents of Pralidoxime Chloride Diluent (2mL)

Table 7.6 AtroPen®: Comparison of AtroPen® Autoinjectors (Based on Dose Strengths)

Table 7.7 Diazepam Autoinjector C-IV: Constituents of Diazepam Diluent (1 mL)

Table 7.8 DuoDote® Autoinjector: Constituents of Atropine Diluent (0.7mL)

Table 7.9 DuoDote® Autoinjector: Constituents of Pralidoxime Chloride Diluent (2mL)

Table 7.10 Morphine Autoinjector C-II: Constituents of Diluent

Table 7.11 Pralidoxime Chloride Autoinjector: Constituents of Diluent (2mL)

Table 7.12 Meridian Medical Technologies: Comparison of Autoinjectors

Table 7.13 Owen Mumford: Comparison of AutoJect® 2 Variants

Table 7.14 Owen Mumford: Comparison of Autoject® 2 Variants Based on Size of the Needle

Table 7.15 Owen Mumford: Comparison of Autoject® Mini Variants Based on Size

Table 7.16 Owen Mumford: Autoject® Flex Variants (Features)

Table 7.17 Owen Mumford: Comparison of Autoinjectors

Table 7.18 SHL: Comparison of Two-Step Disposable Autoinjectors

Table 7.19 SHL: Comparison of Three-Step Disposable Autoinjectors

Table 7.20 Union Medico: Comparison of 45° Autoinjectors

Table 7.21 Union Medico: Comparison of 90° Autoinjectors

Table 7.22 Ypsomed: Comparison of Autoinjectors

Table 10.1 Emerging Indications for Autoinjectors

Table 13.1 Autoinjectors: Distribution by Players

Table 13.2 Autoinjectors: Distribution by Type of Primary Drug Container

Table 13.3 Autoinjectors: Distribution by Usability

Table 13.4 Autoinjectors: Distribution by Type of Dosage

Table 13.5 Autoinjectors: Distribution by Route of Administration

Table 13.6 Approved Combination Products: Distribution by Players

Table 13.7 Approved Combination Products: Distribution by Indication

Table 13.8 Approved Combination Products: Distribution by Type of Primary Drug Container

Table 13.9 Approved Combination Products: Distribution by Usability

Table 13.10 Approved Combination Products: Distribution by Route of Administration

Table 13.11 Autoinjectors: Distribution by Target Drug

Table 13.12 Adrenaline / Epinephrine: Historical Sales (USD Million), 2012 - 2014

Table 13.13 Interferon beta-1a: Historical Sales (USD Million), 2012 - 2014

Table 13.14 Interferon beta-1a: Historical Sales (USD Million), 2012 - 2014

Table 13.15 Bespak Sales (GBP Million), FY 2010-H1 2016

Table 13.16 Ypsomed Sales (CHF Million), FY 2011- H1 2016

Table 13.17 Ypsomed: Sales by Business Divisions (CHF Million, %), FY 2015

Table 13.18 Ypsomed: Sales by Business Divisions (CHF Million, %), H1 2016

Table 13.19 Overall Autoinjectors Market (Number of Units, Millions), 2016 – 2026

Table 13.20 Overall Autoinjectors Market (USD Million), 2016 – 2026

Table 13.21 Regional Autoinjectors Market (Number of Units, Millions), 2016 - 2026

Table 13.22 Regional Autoinjectors Market (USD Million), 2016 – 2026

Table 13.23 Overall Disposable Autoinjectors Market (Number of Units, Million), 2016 – 2026

Table 13.24 Overall Disposable Autoinjectors Market (USD Million), 2016 - 2026

Table 13.25 Overall Reusable Autoinjectors Market (Number of Units, Million), 2016 - 2026

Table 13.26 Overall Reusable Autoinjectors Market (USD Million), 2016 - 2026

Table 13.27 Overall Subcutaneous Autoinjectors Market (Number of Units, Million), 2016 - 2026

Table 13.28 Overall Subcutaneous Autoinjectors Market (USD Million), 2016 – 2026

Table 13.29 Overall Intramuscular Autoinjectors Market (Number of Units, Million), 2016 - 2026

Table 13.30 Overall Intramuscular Autoinjectors Market (USD Million), 2016 - 2026

Table 13.31 Autoinjectors for Anaphylaxis Market (Number of Units, Millions), 2016 - 2026

Table 13.32 Autoinjectors for Anaphylaxis Market (USD Million), 2016 - 2026

Table 13.33 Disposable Autoinjectors for Anaphylaxis (Number of Units, Million), 2016 - 2026

Table 13.34 Disposable Autoinjectors for Anaphylaxis (USD Million), 2016 - 2026

Table 13.35 Reusable Autoinjectors for Anaphylaxis (Number of Units, Million), 2016 - 2026

Table 13.36 Reusable Autoinjectors for Anaphylaxis (USD Million), 2016 - 2026

Table 13.37 Subcutaneous Autoinjectors for Anaphylaxis (Number of Units, Million), 2016 - 2026

Table 13.38 Subcutaneous Autoinjectors for Anaphylaxis (USD Million), 2016 - 2026

Table 13.39 Intramuscular Autoinjectors for Anaphylaxis (Number of Units, Million), 2016 - 2026

Table 13.40 Intramuscular Autoinjectors for Anaphylaxis (USD Million), 2016 - 2026

Table 13.41 Autoinjectors for Multiple Sclerosis Market (Number of Units, Million), 2016 - 2026

Table 13.42 Autoinjectors for Multiple Sclerosis Market (USD Million), 2016 - 2026

Table 13.43 Disposable Autoinjectors for Multiple Sclerosis (Number of Units, Million), 2016 - 2026

Table 13.44 Disposable Autoinjectors for Multiple Sclerosis (USD, Million), 2016 - 2026

Table 13.45 Reusable Autoinjectors for Multiple Sclerosis (Number of Units, Million), 2016 – 2026

Table 13.46 Reusable Autoinjectors for Multiple Sclerosis (USD Million), 2016 - 2026

Table 13.47 Subcutaneous Autoinjectors for Multiple Sclerosis (Number of Units, Million), 2016 -2026

Table 13.48 Subcutaneous Autoinjectors for Multiple Sclerosis (USD Million), 2016 - 2026

Table 13.49 Intramuscular Autoinjectors for Multiple Sclerosis (Number of Units, Million), 2016 – 2026

Table 13.50 Intramuscular Autoinjectors for Multiple Sclerosis (USD Million), 2016 - 2026

Table 13.51 Autoinjectors for Rheumatoid Arthritis Market (Number of Units, Million), 2016 - 2026

Table 13.52 Autoinjectors for Rheumatoid Arthritis Market (USD Million), 2016 - 2026

Table 13.53 Disposable Autoinjectors for Rheumatoid Arthritis (Number of Units, Million), 2016 - 2026

Table 13.54 Disposable Autoinjectors for Rheumatoid Arthritis (USD Million), 2016 - 2026

Table 13.55 Reusable Autoinjectors for Rheumatoid Arthritis (Number of Units, Million), 2016 - 2026

Table 13.56 Reusable Autoinjectors for Rheumatoid Arthritis (USD Million), 2016 - 2026

Table 13.57 Subcutaneous Autoinjectors for Rheumatoid Arthritis (Number of Units, Million), 2016 - 2026

Table 13.58 Subcutaneous Autoinjectors for Rheumatoid Arthritis (USD Million), 2016 - 2026

Table 13.59 Intramuscular Autoinjectors for Rheumatoid Arthritis (Number of Units, Million), 2016 - 2026

Table 13.60 Intramuscular Autoinjectors for Rheumatoid Arthritis (USD Million), 2016 - 2026

Table 13.61 Autoinjectors for Migraine Market (Number of Units, Million), 2016 - 2026

Table 13.62 Autoinjectors for Migraine Market (USD Million), 2016 - 2026

Table 13.63 Disposable Autoinjectors for Migraine (Number of Units, Million), 2016 - 2026

Table 13.64 Disposable Autoinjectors for Migraine (USD Million), 2016 - 2026

Table 13.65 Reusable Autoinjectors for Migraine (Number of Units, Million), 2016 - 2026

Table 13.66 Reusable Autoinjectors for Migraine (USD Million), 2016 - 2026

Table 13.67 Subcutaneous Autoinjectors for Migraine (Number of Units, Million), 2016 - 2026

Table 13.68 Subcutaneous Autoinjectors for Migraine (USD Million), 2016 - 2026

Table 13.69 Intramuscular Autoinjectors for Migraine (Number of Units, Million), 2016 - 2026

Table 13.70 Intramuscular Autoinjectors for Migraine (USD Million), 2016 - 2026

Table 13.71 Autoinjectors for Diabetes Market (Number of Units, Million), 2016 - 2026

Table 13.72 Autoinjectors for Diabetes Market (USD Million), 2016 - 2026

Table 13.73 Disposable Autoinjectors for Diabetes (Number of Units, Million), 2016 - 2026

Table 13.74 Disposable Autoinjectors for Diabetes (USD Million), 2016 - 2026

Table 13.75 Reusable Autoinjectors for Diabetes (Number of Units, Million), 2016 - 2026

Table 13.76 Reusable Autoinjectors for Diabetes (USD Million), 2016 - 2026

Table 13.77 Subcutaneous Autoinjectors for Diabetes (Number of Units, Million), 2016 - 2026

Table 13.78 Subcutaneous Autoinjectors for Diabetes (USD Million), 2016 - 2026

Table 13.79 Intramuscular Autoinjectors for Diabetes (Number of Units, Million), 2016 - 2026

Table 13.80 Intramuscular Autoinjectors for Diabetes (USD Million), 2016 - 2026

Table 13.81 Autoinjectors for Other Diseases Market (Number of Units, Million), 2016 - 2026

Table 13.82 Autoinjectors for Other Diseases Market (USD Million), 2016 - 2026

Table 13.83 Disposable Autoinjectors for Other Diseases (Number of Units, Million), 2016 – 2026

Table 13.84 Disposable Autoinjectors for Other Diseases (USD Million), 2016 - 2026

Table 13.85 Reusable Autoinjectors for Other Diseases (Number of Units, Million), 2016 – 2026

Table 13.86 Reusable Autoinjectors for Other Diseases (USD Million), 2016 - 2026

Table 13.87 Subcutaneous Autoinjectors for Other Diseases (Number of Units, Million), 2016 - 2026

Table 13.88 Subcutaneous Autoinjectors for Other Diseases (USD Million), 2016 - 2026

Table 13.89 Intramuscular Autoinjectors for Other Diseases (Number of Units, Million), 2016 - 2026

Table 13.90 Intramuscular Autoinjectors for Other Diseases (USD Million), 2016 – 2026

Table 13.91 Numbers of Biologics Approved by the USFDA, 2009-2015

Table 13.92 Autoinjectors Market (2016, 2026): Distribution by Therapeutic Area (USD Million)

Table 13.93 Autoinjectors Market (2016, 2026): Distribution by Therapeutic Area (Number of Units)

Table 13.94 Autoinjectors Market (2016, 2026): Distribution by Usability (USD Million)

Table 13.95 Autoinjectors Market (2016, 2026): Distribution by Usability (Number of Units)

Table 13.96 Autoinjectors Market (2016, 2026): Distribution by Route of Administration (USD Million)

Table 13.97 Autoinjectors Market (2016, 2026): Distribution by Route of Administration (Number of Units)
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • 3P Limited
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Medeca Pharma
  • PDL BioPharma
  • Sumitomo Dainippon Pharma
  • MORE
With the rising trend towards self-injection devices and rapidly growing pipeline of the biologics / biosimilars, autoinjectors have recently emerged as an important class of medical devices. Compared to conventional delivery systems, these devices automate the process of delivering drugs through subcutaneous or intramuscular routes. Autoinjectors are primarily spring-driven systems and use fillable / prefilled syringes or cartridges as primary containers.

Due to their numerous benefits including easy self-administration, improved patient compliance, reduced anxiety and dosage errors, these devices have gained a lot of popularity from both pharmaceutical companies and end-users. The growing concern about the hazards associated with the needlestick injuries and other safety concerns has given an additional push to the market.

The origin of autoinjectors dates back to 1960s when a self-administered device was developed with a primary motive for use in military purposes to inject the antidote for nerve agents in biological weapons. Subsequently, EpiPen® by Pfizer / Mylan became the first disposable autoinjector to hit the US commercial market and received marketing approval in 1980s for the treatment of anaphylaxis.

Following this, several autoinjectors were approved for various therapeutic indications. Anaphylaxis, so far, has continued to dominate the overall market. Autoinjectors for other chronic / emergency indications such as multiple sclerosis, rheumatoid arthritis, migraine, psoriasis and diabetes have also witnessed rising adoption.

It is well-known that pharmaceutical companies have frequently collaborated with device manufacturing companies to develop innovative drug delivery systems for their respective marketed / pipeline drugs. Several drugs have been approved in combination with autoinjectors in the past few years. Examples of such drugs include SIMPONI®, AVONEX®, PLEGRIDY®, EVZIO®, Repatha™, ORENCIA®, Trulicity®, ACTEMRA®, Otrexup™, Cosentyx® and COPAXONE®. In addition, these devices act as a life cycle management tool for drugs for which the patent has already expired or is close to expiry.

The increased interest has driven medical device manufacturers to introduce next generation of autoinjectors with advanced features and innovative designs making drug administration relatively more safe and convenient. Reformulation of first generation biologics, growing prevalence of chronic diseases, urgent treatment required in emergency conditions, needle safety regulations and technological advancements in this area are some of the factors that will drive this market in the near future.

Example Highlights

- During our research, we identified over 80 autoinjectors being developed or commercially available by more than 20 companies. Over 50 drugs as combination products have been commercialized so far; several companies such as Amgen, GSK, Sanofi and Palatin Technologies are testing their late stage pipeline drugs with autoinjectors.
- Most of the autoinjectors being developed are disposable devices, contributing a share of 62%; reusable / rechargeable / electronic autoinjectors have also emerged providing options for multiple dosing of the drugs.
- Some of the established pharmaceutical stakeholders working in this domain include BD, Bespak, Changzhou Delfu, Elcam Medical, DALI Medical Devices, Meridian Medical Technologies, Owen Mumford, SHL Group, Union Medico, West Pharmaceutical Services and Ypsomed. Several new / small companies have entered with their innovative technologies and devices. Examples of such innovators include Amedra Pharmaceuticals, ChemProtect SK, Future Injection Technologies, Haselmeier AG, Kaleo Pharma, Nuance, Nemera, Oval Medical Technologies, Unilife and Xeris Pharmaceuticals.
- Developers are focusing on introducing a variety of advanced features to make these devices more user-friendly. Specific examples include push-on-skin release, one-handed operation, twist & mix mechanism, automatic reconstitution / priming, anti-roll, compact and sleek designs. Smart electronic autoinjectors are being developed featuring bluetooth connectivity, LCD screen and special software to connect the device or part of the device with computer systems to maintain injection records. Some of the devices, such as Safelia™ autoinjector (Nemera) and Syrina™ AR (Bespak), are also capable of delivering drugs with high volume and high viscosity.
- A variety of novel technologies have emerged for the development of autoinjectors. Examples of such technologies include Breeze™ technology (Nuance Designs), Depot Control technology (Union Medico), VapourSoft™ technology (Bespak), Rotaject™ Pressure Release technology, NIT™ technology, Negasai™ spring technology and Pushclick™ technology (SHL Group).
- Although autoinjectors have been in the market for over two decades, the market is still evolving. There is widespread optimism that such devices hold significant opportunity for the pharmaceutical companies; the rapidly evolving pipeline of biologics and biosimilars will act as a major driver.
- We anticipate the global autoinjectors market to grow at an annualized growth rate of over 8% in the next ten years. Launch in emerging regions such as India and China, availability of such devices for other chronic (in addition to multiple sclerosis and rheumatoid arthritis) and emergency indications (in addition to anaphylaxis), introduction of life cycle management projects for drugs nearing patent expiry are some of the opportunity areas wherein the companies are likely to focus on.

Note: Product cover images may vary from those shown
5 of 5
- 3P Limited
- ALK-Abelló A/S
- AbbVie
- Ablynx
- Aguettant
- Allergy Therapeutics
- Alliance Healthcare
- Allozyne (Acquired by MedImmune)
- Amag Pharmaceuticals
- Amedra Pharmaceuticals (Acquired by Impax Laboratories)
- Amgen
- Antares Phama
- Aptar Pharma
- Arte Corporation
- Aventis Pharma
- Bang & Olufsen Medicom
- Bayer Healthcare
- Becton Dickinson & Co.
- Bespak
- Biogen Idec
- Bioprojet
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Brunswick Biomedical Corporation
- Cambridge Capital Group
- Cambridge Consultants
- Celgene Corporation
- Central Texas Angel Network
- Changzhou Delfu Technology
- ChemProtect SK
- Chugai Pharmaceutical Co. Ltd
- CiToxLab
- Consort Medical
- Cytheris
- CytoDyn
- DALI Medical Devices
- Daikyo Seiko
- Disetronic
- Dr. Reddy's Laboratories
- EMD Serono
- Elcam Medical
- Eli Lilly
- Emergent Biosolutions
- Exsulin
- FFT Medical
- Future Injection Technologies
- Gerresheimer
- GlaxoSmithKline
- Global Pharma
- Globe Medical Tech
- Haselmeier AG
- Hemispherx Bioscience
- Hoffmann-La Roche
- Hospira
- Immune Response Biopharma
- Immunex
- Injectech
- Ionis Pharmaceuticals
- JHP Pharmaceuticals
- Janssen Biotech
- Jiangsu Delfu medical device
- Johnson & Johnson
- Kaleo (formerly known as Intelliject)
- King Pharmaceuticals
- Kisling AG
- Labrys Biologics (Acquired by Teva)
- Lincoln Medical (Acquired by Bioprojet Pharma)
- Lineage Therapeutics
- LyoGo
- MSD Animal Health
- MedPro
- Medac Pharma
- Medeca Pharma
- Medical Valley Alliance
- Merck
- Merck Serono
- Meridian Medical Technologies
- Merz Pharmaceuticals
- Mylan
- National Health Service
- Nemera
- Nipro Corporation (Acquired MGlas)
- Novartis
- Novo Nordisk
- Nuance Design
- Nuova Ompi
- Nuron Biotech
- Otsuka Pharmaceuticals
- Oval Medical Technologies
- Owen Mumford
- PA Consulting Group
- PDL BioPharma
- PHC Injection Device Technologies
- Palatin Technologies
- Pfizer
- Pharma-Pen
- PhaseBio Pharmaceuticals
- Plas-Tech Engineering
- Project Pharmaceutics
- Redmile Group
- Regeneron Pharmaceuticals
- Revolutions Medical
- Roselabs Bioscience
- SCHOTT AG
- SKINSORB
- Sabby Management
- Sanofi
- Sanofi Pasteur
- Santarus
- Scandinavian Health Limited Group
- School of Medicine at the University of Texas Health Science Center San Antonio
- Schreiner MediPharm
- Sciele Pharma (Now Known as Shionogi Pharma)
- Shandong Weigao Group
- SiO2 Medical Products
- SiliCycle
- Sumitomo Dainippon Pharma
- Sun Pharma
- Survival Technologies
- Taisei Kako
- Takeda
- Team Consulting
- Terumo Corporation
- Teva Pharma Industries
- Texas Diabetes Institute (TDI) of the University Health System
- The Cambridge Angels
- The McNair Group
- The Medical House (TMH)
- Tonghua Dongbao Pharmaceutical
- UCB
- US Medical Instruments
- US WorldMeds
- Uman Pharma
- Unilife Corporation
- Union Medico
- Valeant Pharmaceutical International
- Vetter Pharma
- West Pharmaceutical Services
- Windgap Medical
- Xeris Pharmaceuticals
- Ypsomed Delivery Systems
- Zion Clinical Pharmacy
- medac GmbH
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll